Vertex PharmaceuticalsVRTX
About: Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Employees: 5,400
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
44% more first-time investments, than exits
New positions opened: 174 | Existing positions closed: 121
28% more repeat investments, than reductions
Existing positions increased: 647 | Existing positions reduced: 505
12% more capital invested
Capital invested by funds: $97.7B [Q1] → $110B (+$12.1B) [Q2]
7% more funds holding in top 10
Funds holding in top 10: 30 [Q1] → 32 (+2) [Q2]
4% more funds holding
Funds holding: 1,465 [Q1] → 1,518 (+53) [Q2]
0.05% more ownership
Funds ownership: 91.0% [Q1] → 91.05% (+0.05%) [Q2]
22% less call options, than puts
Call options by funds: $680M | Put options by funds: $875M
Research analyst outlook
18 Wall Street Analysts provided 1 year price targets over the past 3 months
18 analyst ratings
RBC Capital Brian Abrahams 39% 1-year accuracy 25 / 64 met price target | 7%downside $437 | Sector Perform Maintained | 9 Oct 2024 |
Cantor Fitzgerald Olivia Brayer 54% 1-year accuracy 13 / 24 met price target | 3%upside $480 | Overweight Reiterated | 8 Oct 2024 |
RBC Capital Brian Abrahams 39% 1-year accuracy 25 / 64 met price target | 9%downside $425 | Sector Perform Maintained | 4 Oct 2024 |
Morgan Stanley Matthew Harrison 57% 1-year accuracy 12 / 21 met price target | 1%upside $474 | Equal-Weight Maintained | 1 Oct 2024 |
RBC Capital Brian Abrahams 39% 1-year accuracy 25 / 64 met price target | 8%downside $431 | Sector Perform Reiterated | 19 Sept 2024 |
Financial journalist opinion
Based on 22 articles about VRTX published over the past 30 days